Amplia Therapeutics (ASX:ATX) has provided an update on the ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in advanced pancreatic cancer.
Amplia announces second confirmed complete response in ACCENT trial
June 19, 2025 Australian Biotech
Latest Video
New Stories
-
'No data means no prospect of access to trials or funded medicines'
July 30, 2025 - - Latest News -
The problem with the minister's statement is that it's entirely accurate
July 30, 2025 - - Latest News -
Plenty going on behind the scenes, but the industry so far is mostly favouring public silence
July 30, 2025 - - Latest News -
World-first study uses DNA to investigate who develops MS and why
July 30, 2025 - - Latest News -
Government moves on general co-pay as safety net gets further out of reach
July 29, 2025 - - Latest News -
'For these families, genomics is not a luxury—it’s the only viable path'
July 29, 2025 - - Latest News -
Pharmac identifies the wider societal benefit of treatments for chronic conditions
July 28, 2025 - - Latest News